[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630597":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":23,"centralContacts":32,"locations":38,"responsibleParty":53,"collaborators":23,"id":57,"slug":23,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":23,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":23,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":23,"overallStatus":40,"whyStopped":23,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Group L","EXPERIMENTAL","Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.",[13],"Drug: Ondansetron lozenge",{"label":15,"type":10,"description":16,"interventionNames":17},"Group O","Patients will receive 4 mg of ondansetron IV just before the surgery.",[18],"Drug: Ondansetron intravenous",{"label":20,"type":21,"description":22,"interventionNames":23},"Group C","NO_INTERVENTION","Patients will not receive ondansetron as a control group.",null,[25,29],{"type":26,"name":27,"description":11,"armGroupLabels":28,"otherNames":23},"DRUG","Ondansetron lozenge",[9],{"type":26,"name":30,"description":16,"armGroupLabels":31,"otherNames":23},"Ondansetron intravenous",[15],[33],{"name":34,"role":35,"phone":36,"phoneExt":23,"email":37},"Mohammed S Elsharkawy, MD","CONTACT","00201148207870","mselsharkawy@med.tanta.edu.eg",[39],{"facility":5,"status":40,"city":41,"state":42,"zip":43,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Tanta","El-Gharbia","31527","Egypt",{"type":46,"coordinates":47},"Point",[48,49],31.00192,30.78847,{"lat":49,"lon":48},[52],{"name":34,"role":35,"phone":36,"phoneExt":23,"email":37},{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"PRINCIPAL_INVESTIGATOR","Mohammed Said ElSharkawy","Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.","100630597",false,"NCT07489742","Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Tonsillectomy","Effect of Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Tonsillectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age from 4 to 15 years.\n* Both sexes.\n* American Society of Anesthesiology (ASA) physical status I-II.\n* Children undergoing tonsillectomy under general anesthesia.\n\nExclusion Criteria:\n\n* Allergy to ondansetron.\n* History of sleep apnea.\n* Cardiac and respiratory diseases.\n* Upper respiratory tract infection.\n* Taking corticosteroids.","ALL","4 Years","15 Years",{"count":67,"type":68},210,"ESTIMATED","INTERVENTIONAL",[71],"NA","This study aims to compare the effect of ondansetron lozenge and intravenous for prevention of shivering in tonsillectomy.",[74,75,76,77,78],"Ondansetron","Lozenge","Intravenous","Shivering","Tonsillectomy","2026-03-25",{"date":81,"type":82},"2026-03-27","ACTUAL",{"date":79,"type":82},{"date":85,"type":68},"2026-09-01",{"name":5,"class":6},1]